Purpose of the Report

Enclosed is the 2011 Dialysis Facility Report (DFR) for your facility, based on data from the Centers for Medicare & Medicaid Services (CMS).

This DFR includes data specific to provider number(s): 502505

These data could be useful in quality improvement and assurance activities. The information contained in this report facilitates comparisons of patient characteristics, treatment patterns, transplantation rates, hospitalization rates, and mortality rates to local and national averages. Some of these comparisons account for the patient mix at this facility, including age, sex, race, and diabetic status. This report is provided as a resource for characterizing selected aspects of clinical experience at this facility relative to other caregivers in this state, ESRD Network, and across the United States.

In September 2011, each state's surveyor(s) will receive the DFRs with comments (if applicable) for all dialysis facilities in their state.

This report also provides you with advance notice of the updated quality measures (urea reduction ratio, hemoglobin, and patient survival) for your facility that will be reported on the Dialysis Facility Compare (DFC) website in November 2011 (www.medicare.gov).

Collaborators

CMS has contracted with the University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) and Arbor Research Collaborative for Health to produce the *2011 Dialysis Facility Reports*.

How to Submit Comments

Between July 15, 2011 and August 15, 2011, you may submit comments to (1) CMS on the three DFC measures, (2) your state surveyor, or (3) UM-KECC. Please visit www.DialysisReports.org, log on to view your report, and click on the **Comments & Inquiries** tab. If you have questions after the comment period is over, please contact us directly at Support@DialysisReports.org or 1-877-665-1680.

- (1) **Dialysis Facility Compare:** Comment on the three DFC measures (see page 2) which will be reported on the DFC public website in November 2011. The comment period begins July 15, 2011 and ends August 15, 2011. Your comments will be shared with CMS but will **not** appear on the DFC website.
- (2) **State Surveyor:** Comment on your DFR for your state's surveyors. The surveyor(s) in your state will receive a copy of your DFR in September 2011 with your comments.
- (3) **UM-KECC:** Submit questions about your DFR to UM-KECC. You can also submit your suggestions to improve the DFR. These comments will not be shared with CMS or your state surveyor.

NKC LAKE WASHINGTON KIDNEY CENTER State: WA Network: 16 CMS Provider#: 502505

Dear Dialysis Facility Director:

This report has been prepared for this facility by the University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) with funding from the Centers for Medicare & Medicaid Services (CMS). It is the sixteenth in a series of annual reports. This is one of 5,877 reports that have been sent to the ESRD Networks for distribution to ESRD providers in the U.S. Your state survey agency will receive this report in September 2011. Selected highlights from this report are given here. The information specific to this facility is printed in **bold type** for easy identification.

What's New This Year: As part of a continuing effort to improve the quality and relevance of this report for your facility, the following changes have been incorporated into your 2011 DFR. Emergency department and readmission statistics have been added to Table 2. In addition, most of the hospitalization summaries (Table 2) are now calculated for a four-year period. Values for each year from 2007-2010, along with a summarized statistic for the four-year period are reported for Medicare dialysis patients. We also reported the averages in your state, your ESRD Network, and the nation for this combined four-year period. We've added a new table that reports influenza vaccination summary statistics identified on Medicare claims for Medicare dialysis patients treated on December 31st of each year in your facility (Table 5). Average values for 2010 are also reported among patients in your state, Network, and the U.S. A new section on the prescription of erythropoiesis stimulating agents (ESA) and iron has been added to Table 6.

Dialysis Facility Compare Preview: Anemia management is reported as two measures: the percent of patients with hemoglobin values of less than 10 g/dL and the percent of patients with hemoglobin values greater than 12 g/dL. The URR and hemoglobin measures were calculated for Medicare approved dialysis facilities operating at any time during 2010. The hemoglobin measures were calculated only for patients treated with erythropoiesis stimulating agents (ESA). The patient survival measure was calculated for Medicare approved dialysis facilities operating at any time from 2007 through 2010. The following measures for this facility will appear on the DFC website:

	Measure Name	This Facility
1.	The percentage of Medicare hemodialysis patients treated in this facility during 2010 with URR >= 65% Number of patients included in calculation: 75	91%
2.	The percentage of Medicare patients treated in this facility during 2010 with ESA-treated hemoglobin <10 g/dL with ESA-treated hemoglobin >12 g/dL Number of patients included in calculation: 77	0% 14%
3.	Patient survival reported as "as expected," "better than expected," or "worse than expected" for the time period 2007-2010 for this facility Standardized Mortality Ratio (SMR): 0.75 P-value: 0.02	Better than Expected

Please see Table 6 for more information on URR and ESA-treated hemoglobin for this facility. URR and ESA-treated hemoglobin measures based on 10 or fewer patients will be reported as "not available" on DFC. Table 1 provides additional information on patient survival. If the Standardized Mortality Ratio (SMR) is less than 1.00 and statistically significant (p<0.05), the patient survival classification is "Better than Expected" on DFC. If the facility SMR is greater than 1.00 and statistically significant (p<0.05), the patient survival classification is "Worse than Expected" on DFC. Otherwise, the patient survival classification is "As Expected" on DFC. Please note that the classification is not reported for a facility if the SMR is based on 3 or fewer expected deaths.

NKC LAKE WASHINGTON KIDNEY CENTER State: WA Network: 16 CMS Provider#: 502505

Overview: This report includes summaries of patient characteristics, treatment patterns, and patient outcomes for chronic dialysis patients who were treated in this facility between January 2007 and December 2010. Mortality, hospitalization, and transplantation statistics are reported for a three- or four-year period. Regional and national averages are included to allow for comparisons. Several of the summaries of patient mortality, hospitalization, and transplantation are adjusted to account for the characteristics of the patient mix at this facility, such as age, sex, race, ethnicity, and diabetes as a cause of ESRD. Unless otherwise specified, data refer to hemodialysis and peritoneal dialysis patients combined.

Summary data about the percent of patients with URR of 65% or higher (Table 6) and with central catheters (Table 7) are included, as suggested by Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines. These practice pattern measures are strongly correlated with the mortality and hospitalization measures found in these reports. Note that elevated mortality or hospitalization rates may be due to a variety of causes unrelated to clinical practices, so it may not always be possible to identify clinical practices that explain those rates.

Mortality: Mortality summaries are provided in Table 1. Standardized Mortality Ratios (SMR) for all patients and for patients in their first year of ESRD treatment are calculated for each facility. Although mortality statistics can vary substantially from year to year, they are reported here as a key outcome for dialysis patients. The SMR compares the observed death rate in this facility to the death rate that would be expected based on national death rates for patients with the characteristics of the patients at this facility. For the overall SMR, time at risk and deaths within 60 days after transfer out of this facility are attributed to this facility. The first year SMR includes all incident patients at the facility for their entire first year of dialysis whether they transfer out of the facility or not. Time at risk and deaths after transplantation are excluded from the analysis. The SMR is adjusted for patient age, sex, race, ethnicity, diabetes as a cause of ESRD, duration of ESRD, nursing home status, body mass index (BMI) at incidence, comorbidities at incidence, and state population death rates. Additionally, each year's estimate is compared to the US mortality rates for the same year. The rate of withdrawal from dialysis and the percentage of deaths due to infection and cardiac related deaths are reported in the table to help in the interpretation of the mortality outcomes.

There was a 19% annual observed death rate among the patients treated at this facility during 2007-2010, while a rate of 25% would be expected after adjustment for the factors listed above. The SMR of observed to expected deaths is 0.75, which is 25% fewer deaths than expected at this facility. Among all U.S. facilities, only 15% of facilities had an SMR lower than 0.75. This difference is statistically significant (p<0.05), so this lower mortality is unlikely to be due to random chance and probably represents a real difference from the expected mortality in the nation.

There was a 17% annual observed first year death rate among the patients starting dialysis at this facility during 2007-2009, while a rate of 32% would be expected after adjustment for the factors listed above. The first year SMR of observed to expected deaths is 0.53, which is 47% fewer deaths than expected at this facility. Among all U.S. facilities, only 14% of facilities had an SMR lower than 0.53. This difference is statistically significant (p<0.05), so this lower mortality is unlikely to be due to random chance and probably represents a real difference from the expected mortality in the nation.

Hospitalization: Hospitalization summaries are reported for Medicare patients in Table 2. The table includes information on the number of days hospitalized, the number of hospital admissions and the diagnoses present at admission, and the number of emergency department (ED) visits for patients at this facility. The Standardized Hospitalization Ratio (SHR) for Days, Admissions, and ED visits compares the observed number of events (be it days hospitalized, admissions, or ED visits) to the number that would be expected based on national rates for patients with the characteristics of the patients at this facility. The three measures are adjusted for age, sex, diabetes, duration of ESRD, nursing home status, BMI, and comorbidities at incidence. Additionally, each year's estimate is compared to the US rates for the same year. As in the mortality calculation, time at risk and events within 60 days after transfer out of this facility are attributed to this facility. Time at risk and events starting 3 days before transplantation are excluded from the analysis.

The SHR (Days) of observed to expected number of days hospitalized at this facility during 2007-2010 is 0.43, which is 57% lower than expected. The SHR (Admissions) of observed to expected number of admissions for patients at this facility during 2007-2010 is 0.63, which is 37% lower than expected. The SHR (ED) of observed to expected number of ED visits for patients at this facility during 2007-2009 is 0.66, which is 34% lower than expected.

Infection: Information on hospitalizations for septicemia reported in Table 2 is based on Medicare patient claims.

NKC LAKE WASHINGTON KIDNEY CENTER State: WA Network: 16 CMS Provider#: 502505

The percentage of Medicare dialysis patients at this facility hospitalized with septicemia during 2007-2010 was 7%, compared to 11% nationally.

Transplantation: Transplantation summaries are reported in Table 3. The Standardized Transplantation Ratio (STR) represents relative first transplantation rates (observed/expected) for patients at this facility adjusting for patient age. Additionally, each year's estimate is compared to the US transplantation rates for the same year. Patients who are 70 or older as well as those with a prior kidney transplant are excluded. As in the mortality and hospitalization calculations, time at risk and transplants within 60 days after transfer out of this facility are attributed to this facility.

Of the patients under age 70 treated at this facility during 2007-2010 who had not previously received a transplant, 15% were transplanted annually, while a rate of 5% would be expected for these patients. The STR of observed to expected number of patients transplanted for this facility is 3.24, which is 224% higher than expected for this facility. This difference is statistically significant (p<0.05) and is unlikely to be due to random chance.

Transplant Waitlist: Table 4 summarizes waitlist information for patients under age 70 being treated at this facility at the end of each year. Unlike the mortality, hospitalization, and transplantation statistics, the waitlist statistics do not include patients who transferred out of the facility.

Among the 45 dialysis patients under age 70 treated at this facility on December 31, 2010, 42% were on the kidney transplant waitlist compared to 24% nationally. This difference is statistically significant (p<0.05) and is unlikely to be due to random chance.

Influenza Vaccination: Table 5 summarizes influenza vaccination information for Medicare patients being treated at this facility at the end of each year. Similar to the waitlist table, influenza vaccination statistics do not include patients who transferred out of the facility.

Among the 69 Medicare dialysis patients treated at this facility on December 31, 2009, 93% were vaccinated between September 1 and December 31, 2009 compared to 69% nationally. This difference is statistically significant (p<0.05) and is unlikely to be due to random chance.

Practice Patterns: Table 6 summarizes the dialytic modality, hemoglobin, and URR for patients treated at this facility during each year. These data are derived from CMS Medicare paid dialysis claim data. Vascular access data for prevalent and incident patients as reported by the CMS Fistula First project are summarized in Table 7.

There were 77 ESA-treated dialysis patients included in the analysis of Medicare claims data of hemoglobin for 2010 at this facility. The average hemoglobin calculated for these patients is 11.4, g/dL compared to 11.4 g/dL nationally. Among the 75 hemodialysis patients in this facility included in the analysis of Medicare claims data of URR in 2010, 91% had URR above the KDOQI minimum value for URR (URR \geq 65%), compared to 97% nationally.

At this facility in 2010, an average of 44% of incident patients had arteriovenous (AV) fistulae in place, compared to 35% nationally. Also at this facility in 2010, an average of 81% of prevalent patients had AV fistulae in place, compared to 64% nationally. Of the prevalent patients receiving hemodialysis treatment at this facility in 2010, 1% had a catheter which had been in place for at least 90 days as their only vascular access, compared to 9% nationally. See Tables 6 and 7 for more information about practice patterns.

Patient Characteristics: Characteristics of patients starting dialysis during 2007-2010 are reported in Table 8. Table 9 gives summaries for all dialysis patients being treated at the end of each year, 2007-2010. Comorbidities are reported in Table 10 for Medicare dialysis patients being treated at the end of each year, 2007-2009.

There were 21 patients with Medical Evidence Forms (CMS-2728) which indicated that they started treatment at this facility during 2010. The average number of comorbidities reported for new patients is 3.2, which is equal to the average of 3.2 reported nationally. Also, 24% of these patients were not under the care of a nephrologist before starting dialysis, compared to 30% nationally. Furthermore, 43% of these patients were informed of their transplant options, compared to 77% nationally. The average serum albumin calculated for these patients (before first dialysis) is 3.6 g/dL, which is higher than the national average value of 3.1 g/dL. The average residual renal function (GFR), estimated by the 4-variable MDRD equation, was 8.7 mL/min, which is lower than the national average value of 11.2 mL/min.

Among patients treated at this facility on December 31, 2010, 15% were treated in a nursing home during the year, which is higher than the national average value of 13%. The average number of comorbidities reported on

NKC LAKE WASHINGTON KIDNEY CENTER State: WA Network: 16 CMS Provider#: 502505

Medicare claims in 2009 for Medicare patients in this facility on December 31, 2009 is 3.9, which is lower than the national average value of 4.2.

Facility Information: General information about this facility is provided in Tables 12, 13, and 14. Table 12 provides counts of patients treated, Medicare eligibility, treatment modality, and staffing from the Annual Facility Survey (Form CMS-2744). Table 13 reports survey and certification activity. Table 14 includes services provided by this facility as well as information on ownership.

This facility reported having 25 staff members to care for 83 patients at the end of 2010. This facility reported having 18 stations available as of March 31, 2011. This facility offers both hemodialysis and peritoneal dialysis services. Additional information regarding patient counts, patient modality, and facility staffing is available in Table 12.

Sources of Patient Data: This report is based primarily on Medicare claims and data collected for CMS. Patients were assigned to this facility based on the Standard Information Management System (SIMS) database, Medicare claims, and Medical Evidence Forms (Form CMS-2728). Network 16 has a list of the patients included in the mortality analyses for this facility. Table 10 reports comorbidities reported on Medicare claims. Table 11 reports the number of patients placed in this facility for analyses in Tables 1, 2, 3, 9, and 10 of this report. Table 11 also provides information on patient status at the end of the year, both for patients who remain in this facility until the end of each year, and for those who transfer out of this facility, receive a transplant, or die during the year.

These are just a few highlights of the statistics you will find in this report based on the data for this facility. We hope that this report is of interest to you and that you will discuss it with your staff. We welcome any questions or comments you might have about the content of the current report or any suggestions you might have for future reports. Comments or suggestions can be submitted via the secure site www.DialysisReports.org between July 15, 2011 and August 15, 2011. If you have questions after the comment period is over, please contact us directly at Support@DialysisReports.org or 1-877-665-1680.

For a complete description of the methods used to calculate the statistics in this report, please see the *Guide to the 2011 Dialysis Facility Reports*. The *Guide* is available from ESRD Network 16, and is also on the Dialysis Reports web site at www.DialysisReports.org.

Prepared by

The University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) under contract with the Centers for Medicare & Medicaid Services

TABLE 1: Mortality Summary for All Dialysis Patients (2007-10) & New Dialysis Patients (2007-09)*1

			,	This Faci	lity			nal Average Year, 2007-20	
	Measure Name	2007	2008	2009	2010	2007-2010	State	Network	U.S.
All	Patients: Death Rates								
1a	Patients (n=number)	120	126	118	117	481 *8	97.9	78.7	92.4
1b	Patient years (PY) at risk (n)	83.5	84.3	84.5	81.1	333.4 *8	68.6	54.7	61.4
1c	Deaths (n)	12	22	14	15	63 *8	13.8	11.3	12.
1d	Expected deaths (n)	21.6	22.2	21.7	18.7	84.2 *8	14.7	11.8	12.
1e	Death rate per 100 PY (% of 1b)	14.4	26.1	16.6	18.5	18.9	20.1	20.6	19.
1f	Expected death rate per 100 PY (% of 1b)	25.9	26.3	25.7	23.0	25.3	21.5	21.6	19.
All	Patients: Categories of Death								
1g	Withdrawal from dialysis prior to death (% of 1c)	58.3	27.3	42.9	53.3	42.9	40.3	41.1	25.0
1h	Death due to: Infections (% of 1c)	33.3	22.7	35.7	13.3	25.4	17.5	17.4	16.
	Cardiac causes (% of 1c)	16.7	36.4	35.7	13.3	27.0	30.1	30.2	25.6
1i	Dialysis unrelated deaths *3 (n; excluded from SMR)	1	0	0	0	1 *8	0.2	0.1	0.
All	Patients: Standardized Mortality Ratio (SMR)								
1j	SMR *4	0.56	0.99	0.64	0.80	0.75	0.93	0.95	1.00
1k	P-value*5	0.04	0.99	0.11	0.48	0.02	n/a	n/a	n/a
11	Confidence interval for SMR*6								
	High (95% limit)	0.97	1.50	1.08	1.33	0.96	n/a	n/a	n/
	Low (5% limit)	0.29	0.62	0.35	0.45	0.57	n/a	n/a	n/a
1m	SMR Percentiles for this Facility (i.e. percent of facilities	s with lower i	mortality r	ates)*7					
	In this State	15	66	16	33	18			
	In this Network	14	57	16	37	15			
	In the U.S.	11	52	16	30	15			
Nev	v Patients: First Year Death Rates	2007	2008	2009	2	007-2009	Reg Per	gional Avera Year, 2007-2	ages 2009 *2
1n	New Patients (n=number)	27	27	25		79*8	24.2	19.2	19.1
1o	Patient years (PY) at risk (n)	25.3	22.1	22.6		70.1 *8	20.8	16.5	16.4
1p	Deaths (n)	2	5	5		12*8	5.2	4.2	4.4
1q	Expected deaths (n)	10.1	7.0	5.4		22.5 *8	5.8	4.6	4.4
1r	Death rate per 100 PY	7.9	22.6	22.1		17.1	25.2	25.3	26.7
1s	Expected death rate per 100 PY	40.0	31.7	23.8		32.2	27.8	27.9	26.7
Nev	v Patients: Categories of Deaths								
1t	Withdrawal from dialysis prior to death (% of 1r)	50.0	40.0	0.0		25.0	48.1	52.3	34.2
1u	Death due to: Infections (% of 1r)	0.0	20.0	20.0		16.7	22.0	24.3	22.9
	Cardiac causes (% of 1r)	50.0	20.0	0.0		16.7	35.5	38.0	32.9
Nev	w Patients: First Year Standardized Mortality Ra								
lv.	SMR *4	0.20	0.71	0.93		0.53	n/a	n/a	n/a
lw	P-value*5	<.01	0.60	0.99		0.02	n/a	n/a	n/a
1x	Confidence interval for SMR*6			****					
	High (95% limit)	0.71	1.66	2.17		0.93	n/a	n/a	n/a
	Low (5% limit)	0.02	0.23	0.30		0.28	n/a	n/a	n/a
1y	First Year SMR Percentiles for this Facility (i.e. percent of				ates)*7				
1 y	In this State	8 8	31	53		12			
	III uno state	O							
	In this Network	13	39	56		20			

n/a = not applicable

[*1] See *Guide, Section IV.*[*2] Values are shown for the average facility, annualized.

[*3] Defined as deaths due to street drugs and accidents unrelated to treatment.

[*4] Calculated as a ratio of deaths to expected deaths(1c to 1d for all patients, 1p to 1q for new patients); not shown if there are fewer than 3 expected deaths.

[*5] A p-value less than 0.05 indicates that the difference between the actual and expected mortality is probably real and is not due to random chance alone, while a p-value greater than or equal to 0.05 indicates that the difference could plausibly be due to random chance.

^[*6] The confidence interval range represents uncertainty in the value of the SMR due to random variation.
[*7] All facilities are included in ranking, regardless of the number of expected deaths.
[*8] Sum of 4 years (all patients), or 3 years (new patients), used for calculations; should not be compared to regional averages.

TABLE 2: Hospitalization Summary for Medicare Dialysis Patients *1 , 2007-2010

			T	his Facili	ity			nal Average Year, 2007-20	
	Measure Name	2007	2008	2009	2010	2007-2010	State	Network	U.S.
Me	dicare Dialysis Patients								
2a	Medicare dialysis patients (n)	88	96	93	94	371 *6	78.1	62.1	72.2
2b	Patient years (PY) at risk (n)	61.9	64.9	66.4	66.7	259.9 *6	52.4	40.7	44.8
Day	ys Hospitalized Statistics								
2c	Total days hospitalized (n)	405	370	414	392	1581 *6	495.5	382.0	650.7
2d	Expected total days hospitalized (n)	896.9	960.6	978.4	870.8	3706.7*6	768.0	590.3	651.0
2e	Days hospitalized per PY	6.5	5.7	6.2	5.9	6.1	9.46	9.39	14.5
2f	Expected days hospitalized per PY	14.5	14.8	14.7	13.1	14.3	14.7	14.5	14.5
2g	Standardized Hospitalization Ratio (Days)*3	0.45	0.39	0.42	0.45	0.43	0.65	0.65	1.00
2h	Percentiles for this Facility (i.e. % of facilities with lower hospitalize	ation rates [[days])*4						
	In this State	22	3	7	18	12	n/a	n/a	n/a
	In this Network	22	11	15	21	10	n/a	n/a	n/a
	In the U.S.	6	4	5	6	3	n/a	n/a	n/a
Adı	mission Statistics								
2i	Total admissions (n)	80	83	71	86	320 *6	87.5	67.3	88.3
2j	Expected total admissions (n)	116.6	128.5	133.1	126.9	505.2 *6	104.4	80.5	88.4
2k	Admissions per PY	1.3	1.3	1.1	1.3	1.2	1.7	1.7	2.0
21	Expected admissions per PY	1.9	2.0	2.0	1.9	1.9	2.0	2.0	2.0
2m	Standardized Hospitalization Ratio (Admissions) *3	0.69	0.65	0.53	0.68	0.63	0.84	0.84	1.00
2n	Percentiles for this Facility (i.e. % of facilities with lower hospitalize	ation rates I	admission	ısl)*4					
	In this State	25	20	3	18	11	n/a	n/a	n/a
	In this Network	28	20	8	22	13	n/a	n/a	n/a
	In the U.S.	14	11	5	13	7	n/a	n/a	n/a
2o	Diagnoses Associated with Hospitalization (% of 2a)*5								
20	Septicemia	5.7	5.2	9.7	7.4	7.0	9.9	8.8	11.2
	Acute myocardial infarction	1.1	3.1	1.1	1.1	1.6	4.1	3.9	4.1
	Congestive heart failure	14.8	13.5	10.8	14.9	13.5	18.3	17.2	21.5
	Cardiac dysrhythmia	12.5	14.6	10.8	14.9	13.2	12.5	11.8	12.0
	Cardiac arrest	2.3	2.1	2.2	1.1	1.9	1.7	1.5	1.3
2									
2p	One day admissions (% of 2i)	20.0	18.1	22.5	26.7	21.9	19.3	18.5	13.4
2q	Average length of stay (days per admission; 2c/2i)	5.1	4.5	5.8	4.6	4.9 59 *6	5.7	5.7	7.4
2r 2s	Readmissions within 30 days (n) Admissions that result in readmission within 30 days (% of 2i)	20 25.0	13 15.7	10 14.1	16 18.6	18.4	96.0 27.4	70.8 26.3	110 31.1
28	Admissions that result in readmission within 30 days (% of 21)	23.0	13.7	14.1	16.0	16.4			
Em	ergency Department(ED) Statistics	2007	2008	2009	20	007-2009	Reg	gional Avera Year, 2007-	ages 2000 *2
2t	Total ED visits (n)	127	119	113	20	359 *6	432.4	328.9	385.7
2u	Expected total ED visits (n)	169	183	190		542 *6	454.6	350.1	385.8
2v	ED visits per PY	2.1	1.8	1.7		1.9*6	2.5	2.6	2.8
2w	Expected ED visits per PY	2.7	2.8	2.9		2.8*6	2.7	2.8	2.8
2x	Standardized Hospitalization Ratio (ED)*3	0.75	0.65	0.59		0.66	0.95	0.94	1.00
	Percentiles for this Facility (i.e. % of facilities with lower hospitalize								
-	In this State	12	6	4		6	n/a	n/a	n/a
	In this Network	21	11	10		9	n/a	n/a	n/a
	In the U.S.	20	10	7		9	n/a	n/a	n/a
2z	Patients with ED visit (% of 2a)	55.7	53.1	53.8		54.2 * ⁷	56.0	57.4	57.9
2z 2aa	ED visits that result in hospitalization (% of 2t)	39.4	33.1 45.4	38.9		41.2	41.1	39.2	50.6
zaa 2ab	Admissions that originate in the ED (% of 2i)	62.5	65.1	62.0		63.2*7	63.0	62.0	71.6

 $n/a = not \ applicable.$

n/a = not applicable.

[*1] Based on patients with Medicare as primary insurer; see *Guide, Section V*.

[*2] Values are shown for the average facility, annualized.

[*3] Calculated as ratio of actual to expected events (2e/2f for days, 2k/2l for admissions, and 2v/2w for ED visits); not shown if there are fewer than 5 patient years at risk.

[*4] All facilities are included in ranking, regardless of the number of patient years at risk.

[*5] Includes diagnoses present at admissions and diagnoses added during the hospital stay.

[*6] Sum of 4 years (days and admissions) or 3 years (ED visits), used for calculations; should not be compared to regional averages.

[*7] Percent is based on the sum of three years.

TABLE 3: Transplantation Summary for Dialysis Patients under Age 70*1, 2007-2010

				This Faci	ility			onal Average Year, 2007-20	
	Measure Name	2007	2008	2009	2010	2007-2010	State	Network	U.S.
3a	Eligible patients (n)	59	56	59	63	237 *11	65.6	52.6	63.4
3b	Transplants (n)	3	5	6	5	19*11	3.2	2.5	2.3
3c	Donor type (sums to 3b*3)								
	Living Donor (n)	3	2	1	2	8 *11	1.0	0.9	0.7
	Deceased Donor (n)	0	3	5	3	11*11	2.3	1.7	1.0
Pa	tients who have not Previously Received a Tr	ansplant							
3d	Eligible patients (n)	47	47	51	48	193 *11	58.4	46.9	57.0
3e	Patient years (PY) at risk (n)	29.9	32.0	33.5	32.3	127.8*11	41.2	32.8	38.4
3f	First transplants *4 (n)	3	5	6	5	19*11	2.9	2.2	2.0
3g	Expected First transplants (n)	1.4	1.4	1.5	1.5	5.9*11	2.2	1.7	2.0
3h	First transplant rate per 100 PY	10.0	15.6	17.9	15.5	14.9	7.0	6.8	5.
3i	Expected First transplant rate per 100 PY	4.8	4.5	4.5	4.6	4.6	5.2	5.2	5.
3j	Donor type (sums to 3f*5)								
	Living Donor (n)	3	2	1	2	8 *11	0.8	0.7	0.0
	Deceased Donor (n)	0	3	5	3	11*11	2.1	1.5	1.4
Sta	andardized 1st Transplantation Ratio (STR)	*6							
3k	STR *7					3.24	1.33	1.31	1.00
31	P-value*8					<.01	n/a	n/a	n/a
3m	95% Confidence interval for STR*9								
	Upper limit	•				5.06	n/a	n/a	n/a
	Lower limit	•				1.95	n/a	n/a	n/a
3n	STR Percentiles for this Facility (i.e. percent of faci	lities with lower tr	ansplantat	ion rates)*	10				
	In this State					95	n/a	n/a	n/a
	In this Network					95	n/a	n/a	n/a
	In the U.S.					96	n/a	n/a	n/a

n/a = not applicable.

n/a = not applicable.

[*1] See *Guide, Section VI.*[*2] Values are shown for the average facility, annualized.

[*3] Values may not sum to 3b due to unknown donor type.

[*4] Among first transplants that occurred after the start of dialysis from 2007-2010, 3.9% of transplants in the U.S. were not included because the transplant occurred less than 90 days after the start of ESRD and 0.9% were not included because the patient was not assigned to a facility at time of transplant.

[*5] Values may not sum to 3f due to unknown donor type.

[*6] This section is not reported if there are fewer than 3 expected transplants.

^[*8] Standardized Transplantation Ratio calculated as ratio of actual (3f) to expected (3g) transplants.

[*8] A p-value less than 0.05 indicates that the difference between the actual and expected transplants is probably real and is not due to random chance, while a p-value greater than or equal to 0.05 indicates that the difference is plausibly due to random chance.

^[*9] The confidence interval range represents uncertainty in the value of the STR due to random variation. [*10] All facilities are included in ranking, regardless of the number of expected transplants. [*11] Sum of 4 years used for calculations; should not be compared toregional averages.

Produced by The University of Michigan Kidney Epidemiology and Cost Center (July 2011)

TABLE 4: Waitlist Summary for Dialysis Patients under Age 70 Treated as of December 31st of Each Year*1, 2007-2010

		:	This Fa	cility		Regional Averages *2, 2010			
	Measure Name	2007	2008	2009	2010	State	Network	U.S.	
1a	Eligible patients on 12/31 (n)	44	45	44	45	53.8	44.1	46.	
lb	Patients on the waitlist (% of 4a)	38.6	40.0	34.1	42.2	22.6	19.5	23.	
łc	P-value (compared to U.S. value) *3	0.02	0.01	0.09	<.01	n/a	n/a	n/	
ld	Patients on the waitlist by subgroup (% of corresponding value in 4e)								
	Age < 40	33.3	33.3	33.3	44.4	32.1	28.6	35.	
	Age 40-69	40.0	41.0	34.3	41.7	21.0	17.9	22.	
	Male	42.3	34.5	40.0	44.4	22.8	19.2	23.	
	Female	33.3	50.0	26.3	38.9	22.4	19.9	23.	
	African American	50.0	50.0	0.0	20.0	23.2	19.7	21.	
	Asian/Pacific Islander	11.1	33.3	44.4	53.8	25.3	24.3	35.	
	Native American					14.9	14.3	17.	
	White, Hispanic	33.3	25.0	33.3	25.0	22.8	18.3	26.	
	White, Non-Hispanic	44.8	40.6	38.5	43.5	22.2	19.3	23.	
	Other/unknown race	100	100		•	21.2	20.0	25.	
	Diabetes	31.3	38.9	38.9	29.4	17.6	14.2	19.	
	Non-diabetes	42.9	40.7	30.8	50.0	26.8	23.8	27.	
	Previous kidney transplant	37.5	50.0	71.4	75.0	43.5	39.0	46	
	No previous kidney transplant	38.9	37.8	27.0	30.3	20.1	17.0	21	
	< 2 years since start of ESRD	36.8	33.3	17.6	40.0	17.2	14.4	15.	
	2-4 years since start of ESRD	50.0	54.5	50.0	27.3	25.3	21.8	27.	
	5+ years since start of ESRD	33.3	37.5	41.2	52.6	27.4	24.3	29.	
e	Eligible patients in 4a by subgroup (n)								
	Age < 40	9	6	9	9	7.9	6.5	6	
	Age 40-69	35	39	35	36	45.9	37.6	40	
	Male	26	29	25			25.3	26.	
	Female	18	16	23 19	27 18	30.5 23.3	18.8	20.	
	African American	2	2	6	5	7.6	4.8	19.	
	Asian/Pacific Islander	9	6	9	13	7.2	4.2	2	
	Native American	0	0	0	0	1.6	2.1	0	
	White, Hispanic	3	4	3	4	5.8	4.7	7.	
	White, Non-Hispanic	29	32	26	23	31.1	28.0	16	
	Other/unknown race	1	1	0	0	0.5	0.3	0.	
	Diabetes	16	18	18	17	24.5	19.7	20	
	Non-diabetes	28	27	26	28	29.4	24.4	25.	
	Previous kidney transplant	8	8	7	12	5.9	4.9	4	
	No previous kidney transplant	36	37	37	33	47.9	39.2	42.	
	< 2 years since start of ESRD	19	18	17	15	22.1	18.3	17.	
	2-4 years since start of ESRD	10	11	10	11	15.5	12.7	14.	
	5+ years since start of ESRD	15	16	17	19	16.3	13.1	14.	

n/a = not applicable
[*1] See *Guide, Section VII.*[*2] Values are shown for the average facility.
[*3] Facility waitlist percentage is compared to the U.S. waitlist percentage for that year: 23.8% (2007), 24.0% (2008), 24.2% (2009), 23.8% (2010).

A p-value greater than 0.05 indicates that the difference between percent of patients waitlisted at the facility and national percentage is plausibly due to random chance.

TABLE 5: Influenza Vaccination Summary for Medicare Dialysis Patients Treated on December 31st of Each Year*1, Flu Seasons September 2007-March 2010

		TI	his Facilit	y	Regi 2	onal Averag 2009-2010* ²	es,
	Measure Name	2007-08	2008-09	2009-10	State	Network	U.S.
5a	Eligible patients on 12/31 (n)	63	66	69	58.2	44.8	49.1
5b	Patients vaccinated between Sep. 1 and Dec. 31 (% of 5a)	88.9	87.9	92.8	75.4	70.8	69.0
5c	P-value *3 (for 5b compared to U.S. value *4)	<.01	<.01	<.01	n/a	n/a	n/a
5d	Patients vaccinated between Sep. 1 and Mar. 31 (% of 5a)	88.9	89.4	92.8	77.6	72.3	70.3
5e	P-value *3 (for 5d compared to U.S. value *5)	<.01	<.01	<.01	n/a	n/a	n/a
5f	Patients vaccinated between Sep. 1 and Dec. 31						
	by subgroup (% of corresponding value in 5g)						
	Age < 18				62.5	58.3	49.5
	Age 18-39	100	75.0	83.3	70.3	67.2	64.8
	Age 40-64	75.0	81.8	83.3	75.1	70.9	68.6
	Age 65-74	82.4	82.6	90.5	74.1	69.8	69.8
	Age 75+	96.6	96.4	100	79.2	73.4	70.8
	Male	86.5	88.6	93.2	74.6	70.4	69.3
	Female	92.3	86.4	92.0	76.4	71.4	68.7
	African American	50.0	100	83.3	71.8	67.4	65.4
	Asian/Pacific Islander	100	100	100	83.5	77.5	70.8
	Native American	100		100	70.5	54.6	73.2
	White	89.4	85.2	92.0	74.8	71.5	71.3
	Other/unknown race	0.0	100		82.4	75.0	65.0
	Hispanic	50.0	66.7	100	83.2	79.3	71.5
	< 1 year since start of ESRD	90.9	90.0	81.8	66.9	61.7	58.4
	1-2 years since start of ESRD	95.0	92.3	100	75.1	71.7	69.2
	3+ years since start of ESRD	84.4	83.3	91.7	78.5	73.8	72.4
5g	Eligible patients in 5a by subgroup (n)						
	Age < 18	0	0	0	< 1.0	< 1.0	< 1.0
	Age 18-39	5	4	6	5.1	4.2	3.9
	Age 40-64	12	11	12	24.4	19.2	21.5
	Age 65-74	17		21	14.4	10.9	12.1
	Age 75+	29		30	14.1	10.4	11.4
	Male	37	44	44	32.6	25.2	26.6
	Female	26	22	25	25.6	19.6	22.5
	African American	2		6	7.0	4.0	18.4
	Asian/Pacific Islander	12		12	6.9	3.8	2.1
	Native American	1		1	1.6	2.1	0.8
	White	47		50	42.5	34.7	27.3
	Other/unknown race	1		0	0.3	0.1	0.5
	Hispanic	2		2	5.3	4.0	7.1
	< 1 year since start of ESRD	11		11	10.7	8.7	8.6
	1-2 years since start of ESRD	20			17.3	13.4	14.3
	3+ years since start of ESRD	32			30.3	22.8	26.2

n/a = not applicable
[*1] Based on patients with Medicare as primary insurer; see *Guide, Section VIII*.
[*2] Values are shown for the average facility.

^[*3] A p-value greater than or equal to 0.05 indicates that the difference between percent of patients vaccinated at the facility and national percentage is plausibly due to random chance. [*4] Compared to the U.S. value for that year and time period (9/1-12/31): 63.3% (2007-08), 64.2% (2008-09), 69.0% (2009-10). [*5] Compared to the U.S. value for that year and time period (9/1-3/31): 63.8% (2007-08), 64.9% (2008-09), 70.3% (2009-10).

TABLE 6: Facility Modality, Hemoglobin, and Urea Reduction Ratio for Medicare Dialysis Patients *1 , 2007-2010

			This Fa	cility		Regiona	l Averages *	² , 2010
	Measure Name	2007	2008	2009	2010	State	Network	U.S.
Mo	dality (among all dialysis patients with ESRD for 9	90+ days and 1+ cla	im at this	s facility)				
6a	Patients treated during year (n)	111	111	111	125	100.5	76.4	75.0
6b	Patients months treated during year (n) *3	798	841	876	886	723.5	542.4	558.3
6c	Modality (% of 6b; sums to 100%)							
	Hemodialysis	99.9	99.4	99.7	99.8	85.4	85.3	92.5
	CAPD/CCPD	0.0	0.0	0.0	0.0	7.2	10.0	6.6
	Other dialysis *4	0.1	0.6	0.3	0.2	7.4	4.7	0.9
6d	Percent of patient months prescribed ESA by Modality *5							
	Hemodialysis	100	100	100	100	100	100	100
	CAPD/CCPD					83.7	83.2	81.1
6e	Percent of patient months prescribed Iron by Modality *5							
	Hemodialysis	77.7	66.0	68.8	60.5	64.1	63.1	60.5
	CAPD/CCPD					16.0	12.7	14.3
He	moglobin (among ESA-treated dialysis patients wi	th ESRD for 90+ da	ys and 4	+ Hemog	lobin clair	ns at this fa	cility)	
6f	Eligible patients (n)	70	75	73	77	59.0	44.6	49.0
6g	Average hemoglobin (g/dL)	11.9	11.8	11.7	11.4	11.4	11.4	11.4
6h	Hemoglobin categories (% of 6f; sums to 100%)							
	< 10 g/dL	0.0	1.3	0.0	0.0	2.3	2.6	3.1
	10-11 g/dL	1.4	2.7	5.5	13.0	18.5	18.3	18.0
	11-12 g/dL	62.9	70.7	76.7	72.7	68.0	68.5	68.2
	> 12 g/dL	35.7	25.3	17.8	14.3	11.2	10.6	10.7
6i	Eligible hemodialysis (HD) patients (n)*6	70	75	73	77	55.2	42.4	50.1
6j	Hemoglobin categories among HD pts (% of 6i; sums to	100%)						
	< 10 g/dL	0.0	0.0	0.0	0.0	2.4	2.8	3.2
	10-11 g/dL	1.4	4.0	5.5	13.0	18.1	17.6	17.5
	11-12 g/dL	62.9	70.7	76.7	72.7	68.4	69.0	68.5
	> 12 g/dL	35.7	25.3	17.8	14.3	11.2	10.6	10.8
6k	Eligible peritoneal dialysis (PD) patients (n) *6	0	0	0	0	11.1	11.2	9.6
61	Hemoglobin categories among PD pts (% of 6k; sums to							
	< 10 g/dL					5.8	6.9	8.3
	10-11 g/dL					30.4	29.1	27.1
	11-12 g/dL					49.5	50.7	51.6
	> 12 g/dL					14.3	13.2	13.0
Ur	ea Reduction Ratio (URR; among HD patients wit	h ESRD for 183+ ds	avs and 4	+ URR c	laims at th	4	7	
6m	Eligible patients (n)	70	73	77	75	52.6	39.2	44.6
6n	URR categories (% of 6m; sums to 100%)	,,	, 5		,,,	52.0	57.2	
011	< 60.0 %	1.4	2.7	3.9	6.7	0.9	1.0	1.1
	60.0-64.9 %	2.9	1.4	2.6	2.7	1.8	2.0	2.3
	65.0-69.9 %	8.6	5.5	5.2	2.7	5.8	7.5	10.8
	70.0-74.9 %	24.3	39.7	31.2	30.7	26.6	30.8	35.6
	75+ %	62.9	50.7	57.1	57.3	64.8	58.7	50.2
<i>c</i> -								
60	URR 65+ (% of 6m; meets a KDOQI guideline) URR percentiles for this facility (i.e. % of facilities with a	95.7	95.9	93.5	90.7	97.3	97.0	96.6
6р	In this State	smaller percentage of p	25	ın UKK 65 18		n/a	n/a	n/a
	In this Network	31	28	14	5 7	n/a n/a	n/a n/a	n/a n/a
	In the U.S.	35	34	16	9	n/a	n/a	n/a

n/a = not applicable

[*1] See *Guide, Section IX.*[*2] Values are shown for the average facility.

[*3] Patients may be counted up to 12 times per year.

[*4] Other dialysis includes patients who switch between HD and PD during the month and patients for whom modality is unknown or missing.

[*5] Percent of patient months represented by the corresponding modality percent in 6c.

[*6] Sum of eligible HD and PD patients may not add to 6f.

[*7] Claims identified as having 4 or more dialysis sessions per week were excluded from the URR calculations. Among eligible claims in the US, 1.33% were excluded due to frequent dialysis in 2007-2010.

TABLE 7: Vascular Access Information (CMS Fistula First)*1, 2007-2010

		Regiona	l Averages *2	, 2010			
Measure Name	2007	2008	2009	2010	State	Network	U.S.
scular Access							
Prevalent hemodialysis patient months *3	1116	1149	1133	1081	n/a	n/a	n/a
Vascular access type in use (% of 7a; sums to 100%)							
Arteriovenous fistula	63.9	70.6	73.3	72.1	66.3	65.4	56.0
Arteriovenous graft	15.8	13.1	11.7	16.2	12.1	12.6	20.4
Catheter	20.3	16.3	15.0	11.7	21.6	22.0	23.5
Other/Missing	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Arteriovenous fistulae in place (% of 7a)*4	75.8	78.9	81.9	80.7	75.5	74.3	63.8
Catheter only $>= 90$ days (% of 7a)*5	5.4	5.0	4.5	0.9	7.5	7.8	9.2
scular Access at First Treatment							
Incident hemodialysis patients (n)	26	20	21	16	20.5	17.9	17.0
Vascular access type in use (% of 7e; sums to 100%)*6							
Arteriovenous fistula	30.8	40.0	14.3	18.8	23.9	24.0	17.4
Arteriovenous graft	7.7	0.0	4.8	18.8	3.6	3.6	7.7
Catheter	61.5	60.0	81.0	62.5	72.4	72.3	74.7
Other/Missing	0.0	0.0	0.0	0.0	0.1	0.1	0.2
Arteriovenous fistulae in place (% of 7e) *4	57.7	55.0	38.1	43.8	43.3	41.3	34.9
	Prevalent hemodialysis patient months *3 Vascular access type in use (% of 7a; sums to 100%) Arteriovenous fistula Arteriovenous graft Catheter Other/Missing Arteriovenous fistulae in place (% of 7a) *4 Catheter only >= 90 days (% of 7a) *5 scular Access at First Treatment Incident hemodialysis patients (n) Vascular access type in use (% of 7e; sums to 100%) *6 Arteriovenous fistula Arteriovenous graft Catheter Other/Missing	Secular Access Prevalent hemodialysis patient months *3 1116 Vascular access type in use (% of 7a; sums to 100%) 63.9 Arteriovenous fistula 63.9 Arteriovenous graft 15.8 Catheter 20.3 Other/Missing 0.0 Arteriovenous fistulae in place (% of 7a) *4 75.8 Catheter only >= 90 days (% of 7a) *5 5.4 secular Access at First Treatment Incident hemodialysis patients (n) 26 Vascular access type in use (% of 7e; sums to 100%) *6 30.8 Arteriovenous fistula 30.8 Arteriovenous graft 7.7 Catheter 61.5 Other/Missing 0.0	Measure Name 2007 2008 scular Access Prevalent hemodialysis patient months *3 1116 1149 Vascular access type in use (% of 7a; sums to 100%)	scular Access Prevalent hemodialysis patient months *3 1116 1149 1133 Vascular access type in use (% of 7a; sums to 100%) 63.9 70.6 73.3 Arteriovenous fistula 63.9 70.6 73.3 Arteriovenous graft 15.8 13.1 11.7 Catheter 20.3 16.3 15.0 Other/Missing 0.0 0.0 0.0 Arteriovenous fistulae in place (% of 7a) *4 75.8 78.9 81.9 Catheter only >= 90 days (% of 7a) *5 5.4 5.0 4.5 scular Access at First Treatment Incident hemodialysis patients (n) 26 20 21 Vascular access type in use (% of 7e; sums to 100%) *6 Arteriovenous fistula 30.8 40.0 14.3 Arteriovenous graft 7.7 0.0 4.8 Catheter 61.5 60.0 81.0 Other/Missing 0.0 0.0 0.0	Measure Name 2007 2008 2009 2010 Scular Access Prevalent hemodialysis patient months *3 1116 1149 1133 1081 Vascular access type in use (% of 7a; sums to 100%) Arteriovenous fistula 63.9 70.6 73.3 72.1 Arteriovenous graft 15.8 13.1 11.7 16.2 Catheter 20.3 16.3 15.0 11.7 Other/Missing 0.0 0.0 0.0 0.0 Arteriovenous fistulae in place (% of 7a) *4 75.8 78.9 81.9 80.7 Catheter only >= 90 days (% of 7a) *5 5.4 5.0 4.5 0.9 scular Access at First Treatment Incident hemodialysis patients (n) 26 20 21 16 Vascular access type in use (% of 7e; sums to 100%) *6 30.8 40.0 14.3 18.8 Arteriovenous fistula 30.8 40.0 14.3 18.8 Arteriovenous graft 7.7 0.0 4.8 18.8	Measure Name 2007 2008 2009 2010 State Scular Access Prevalent hemodialysis patient months *3 1116 1149 1133 1081 n/a Vascular access type in use (% of 7a; sums to 100%) Arteriovenous fistula 63.9 70.6 73.3 72.1 66.3 Arteriovenous graft 15.8 13.1 11.7 16.2 12.1 Catheter 20.3 16.3 15.0 11.7 21.6 Other/Missing 0.0 0.0 0.0 0.0 0.0 Arteriovenous fistulae in place (% of 7a) *4 75.8 78.9 81.9 80.7 75.5 Catheter only >= 90 days (% of 7a) *5 5.4 5.0 4.5 0.9 7.5 Scular Access at First Treatment Incident hemodialysis patients (n) 26 20 21 16 20.5 Vascular access type in use (% of 7e; sums to 100%) *6 30.8 40.0 14.3 18.8 23.9 Arteriovenous graft	Measure Name 2007 2008 2009 2010 State Network Scular Access Prevalent hemodialysis patient months *3 1116 1149 1133 1081 n/a n/a Vascular access type in use (% of 7a; sums to 100%) Arteriovenous fistula 63.9 70.6 73.3 72.1 66.3 65.4 Arteriovenous graft 15.8 13.1 11.7 16.2 12.1 12.6 Catheter 20.3 16.3 15.0 11.7 21.6 22.0 Other/Missing 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Arteriovenous fistulae in place (% of 7a)*4 75.8 78.9 81.9 80.7 75.5 74.3 Catheter only >= 90 days (% of 7a)*5 5.4 5.0 4.5 0.9 7.5 7.8 Scular Access at First Treatment Incident hemodialysis patients (n) 26 20 21 16 20.5 17.9 Vascular access t

n/a = not applicable

[*1] See *Guide, Section X*.

[*2] Values are shown for the average facility.

[*3] Patients may be counted up to 12 times per year.

[*4] Includes all patients with fistulae, regardless of whether or not they received their hemodialysis treatments using their fistulae.

[*5] Catheter was used for treatment and has been in place for 90 days or more prior to treatment. Patient does not have an fistula or graft in place. Catheter is only access. Port access devices are reported as catheters for this project.

reported as catheters for this project.

[*6] Patients listed as graft or catheter may have had fistulae in place for future use, but they actually received their treatment through a graft or catheter.

TABLE 8: Characteristics of New Dialysis Patients*1, 2007-2010 (Form CMS-2728)

			This Fa	cility		Regiona	l Averages *	, 2010
	Measure Name	2007	2008	2009	2010	State	Network	U.S.
Pat	ient Characteristics							
8a	Total number of patients with forms (n)	27	27	25	21	36.4	33.1	30.2
8b	Average age (years [0-95]) *3	69.6	70.2	64.5	69.2	63.5	63.8	63.5
8c	Female (% of 8a)	51.9	18.5	40.0	28.6	44.1	42.5	43.5
8d	Race (% of 8a; sums to 100%)*4							
	African-American	0.0	3.7	16.0	4.8	8.1	6.4	27.9
	Asian/Pacific Islander	7.4	14.8	28.0	19.0	10.3	7.6	4.0
	Native American	3.7	0.0	0.0	0.0	2.0	3.2	1.
	White	88.9	81.5	56.0	76.2	79.0	82.1	66.0
	Other/Unknown/Missing	0.0	0.0	0.0	0.0	0.6	0.7	0.4
8e	Hispanic (% of 8a)	7.4	3.7	0.0	4.8	6.3	6.1	14.0
8f	Primary cause of ESRD (% of 8a; sums to 100%)							
	Diabetes	25.9	29.6	44.0	28.6	47.0	43.6	45.5
	Hypertension	37.0	40.7	24.0	23.8	19.4	21.1	29.1
	Primary Glomerulonephritis	14.8	7.4	24.0	14.3	11.0	10.9	7.2
	Other/Missing	22.2	22.2	8.0	33.3	22.5	24.5	18.3
8g	Medical coverage (% of 8a; sums to 100%)							
~ <u>B</u>	Employer group only	22.2	33.3	20.0	9.5	14.1	13.8	15.1
	Medicare only	25.9	14.8	16.0	19.0	20.5	25.1	23.2
	Medicaid only	3.7	3.7	8.0	9.5	13.1	10.7	11.9
	Medicare and Medicaid only	11.1	14.8	20.0	9.5	11.0	9.6	12.9
	Medicare and Other	25.9	33.3	32.0	42.9	28.3	27.2	21.8
	Other/Unknown	11.1	0.0	4.0	0.0	7.5	7.5	7.9
	None	0.0	0.0	0.0	9.5	5.5	6.2	7.3
8h	Body Mass Index *5							
011	Male	24.9	25.7	24.1	24.2	27.5	27.4	27.5
	Female	30.9	28.7	27.3	25.2	29.0	29.3	28.9
		30.9	20.7	21.3	23.2	29.0	29.3	20.5
8i	Employment *6							
	Six months prior to ESRD treatment	83.3	66.7	57.1	42.9	37.1	38.0	34.0
	At first ESRD treatment	33.3	66.7	57.1	28.6	24.0	24.4	20.3
8j	Primary modality (% of 8a; sums to 100%)							
	Hemodialysis	100	96.3	100	100	91.9	90.1	93.1
	CAPD/CCPD	0.0	3.7	0.0	0.0	7.6	9.6	6.9
	Other/Unknown/Missing	0.0	0.0	0.0	0.0	0.4	0.2	0.0
8k	Number of incident hemodialysis patients (n)	27	26	25	21	32.6	29.2	27.9
81	Access used at first outpatient dialysis (% of 8k; sums to 100%)							
	Arteriovenous fistula	29.6	46.2	12.0	14.3	23.2	23.2	14.9
	Arteriovenous graft	3.7	0.0	4.0	14.3	2.9	2.5	2.9
	Catheter	66.7	53.8	84.0	71.4	73.9	74.2	81.9
	Other/Unknown/Missing	0.0	0.0	0.0	0.0	0.0	0.0	0.2
8m	Arteriovenous fistulae placed (% of 8k)	63.0	53.8	44.0	19.0	41.9	42.6	31.6
	erage Lab Values Prior to Dialysis *3							
8n	Hemoglobin (g/dL [3-18])	10.5	10.7	9.7	9.7	10.0	10.0	9.8
OII	Serum Albumin (g/dL [0.8-6.0])	3.9	3.8	3.6	3.6	3.3	3.2	3.1

(continued)

TABLE 8 (cont.): Characteristics of New Dialysis Patients *1, 2007-2010 (Form CMS-2728)

			This Fa	cility		Regiona	l Averages *2	, 2010
	Measure Name	2007	2008	2009	2010	State	Network	U.S.
Av	erage Lab Values Prior to Dialysis *3							
8p	Serum Creatinine (mg/dL [2-33])	5.7	6.7	6.2	7.9	6.3	6.0	6.2
8q	GFR (mL/min [0-60])	10.5	10.4	9.9	8.7	10.7	11.1	11.2
Ca	re Prior to ESRD Therapy							
8r	Received ESA prior to ESRD (% of 8a)	74.1	70.4	60.0	47.6	30.8	29.9	21.8
8s	Pre-ESRD nephrologist care (% of 8a; sums to 100%)							
	No	3.7	11.1	4.0	23.8	29.0	27.5	30.4
	Yes, < 6 months	11.1	14.8	20.0	28.6	9.7	8.4	13.2
	Yes, 6-12 months	29.6	11.1	20.0	4.8	18.2	20.8	19.1
	Yes, > 12 months	51.9	63.0	56.0	38.1	40.8	40.5	25.1
	Unknown/missing	3.7	0.0	0.0	4.8	2.3	2.8	12.2
8t	Informed of transplant options (% of 8a)	70.4	33.3	72.0	42.9	68.9	67.6	76.7
8u	Patients not informed of transplant options (n)	8	18	7	12	11.7	10.9	7.0
8v	Reason not informed (% of 8u; may not sum to 100%)							
	Medically unfit	37.5	22.2	28.6	50.0	47.0	44.8	31.4
	Unsuitable due to age	0.0	16.7	14.3	0.0	11.3	15.5	24.0
	Psychologically unfit	0.0	5.6	0.0	8.3	3.2	2.5	2.7
	Patient declined information	0.0	0.0	0.0	8.3	1.4	1.3	1.4
	Patient has not been assessed	62.5	61.1	57.1	33.3	36.5	40.3	44.5
Co	morbid Conditions							
8w	Pre-existing Comorbidity (% yes of 8a)							
	Congestive heart failure	37.0	33.3	44.0	42.9	34.2	33.4	32.2
	Atherosclerotic heart disease *7	44.4	51.9	40.0	38.1	25.5	27.1	20.8
	Other cardiac disorder *7	22.2	11.1	4.0	4.8	16.7	15.5	18.2
	CVD, CVA, TIA	11.1	3.7	12.0	0.0	10.2	9.9	9.4
	Peripheral vascular disease	29.6	22.2	24.0	14.3	16.2	16.8	13.6
	History of hypertension	88.9	100	100	95.2	85.4	85.6	86.2
	Diabetes *7	40.7	44.4	56.0	38.1	57.7	55.5	59.1
	Diabetes on insulin	25.9	25.9	36.0	28.6	42.5	39.7	38.2
	COPD	3.7	11.1	4.0	19.0	11.9	11.6	9.7
	Current smoker	3.7	11.1	4.0	4.8	8.2	7.9	6.3
	Cancer	14.8	11.1	4.0	19.0	9.5	9.5	7.7
	Alcohol dependence	0.0	3.7	0.0	0.0	1.6	2.0	1.8
	Drug dependence	0.0	0.0	0.0	4.8	2.3	2.1	1.3
	Inability to ambulate	0.0	3.7	4.0	9.5	6.5	5.8	7.4
	Inability to transfer	0.0	0.0	0.0	0.0	3.4	2.6	3.8
8x	Average number of comorbid conditions	3.2	3.3	3.3	3.2	3.3	3.2	3.2

n/a= not applicable

[*1] See *Guide, Section XI*.

[*2] Values are shown for the average facility.

[*3] For continuous variables, summaries include only responses in range indicated in brackets.

[*4] 'Asian' includes Indian sub-continent. 'Native American' includes Alaskan Native. 'White' includes Middle Eastern and Arabian.

[*5] The median BMI is computed for adult patients at least 20 years old.

[*6] Full-time, part-time, or student (% of 18-60 year olds).

^[47] Atherosclerotic heart disease' includes ischemic heart disease (coronary artery disease) and myocardial infarction. 'Other cardiac disorder' includes cardiac arrest, cardiac dysrhythmia, and pericarditis. 'Diabetes' includes patients with diabetes as the primary cause of ESRD.

TABLE 9: Summaries for All Dialysis Patients Treated as of December 31 of Each Year *1, 2007-2010

			This Fa	cility		Regiona	l Averages *2	, 2010
	Measure Name	2007	2008	2009	2010	State	Network	U.S.
9a	Patients treated on 12/31 (n)	85	88	85	80	74.6	62.3	65.3
9b	Average age (years)	66.8	67.3	65.8	64.6	61.4	61.3	61.2
9c	Age (% of 9a; sums to 100%)							
	< 18	0.0	0.0	0.0	0.0	0.5	0.4	0.4
	18-64	37.6	35.2	35.3	40.0	55.0	55.2	56.2
	65+	62.4	64.8	64.7	60.0	44.5	44.4	43.4
9d	Female (% of 9a)	43.5	36.4	38.8	42.5	44.2	43.4	44.9
9e	Race (% of 9a; sums to 100%)							
	African American	3.5	2.3	7.1	8.8	12.2	9.2	37.3
	Asian/Pacific Islander	17.6	17.0	20.0	27.5	13.0	9.5	5.0
	Native American	1.2	0.0	1.2	0.0	2.6	4.1	1.4
	White	77.6	80.7	71.8	62.5	71.6	76.7	55.1
	Other/Unknown/Missing	0.0	0.0	0.0	1.3	0.7	0.5	1.
9f	Ethnicity (% of 9a; sums to 100%)							
	Hispanic	4.7	4.5	3.5	5.0	9.3	9.2	16.0
	Non-Hispanic	94.1	95.5	96.5	92.5	89.5	89.8	82.4
	Unknown	1.2	0.0	0.0	2.5	1.2	1.0	1.
9g	Cause of ESRD (% of 9a; sums to 100%)							
	Diabetes	34.1	28.4	36.5	33.8	43.8	42.8	44.
	Hypertension	25.9	34.1	25.9	23.8	18.6	18.8	28.
	Glomerulonephritis	16.5	13.6	15.3	17.5	15.4	15.6	11.
	Other/Unknown	23.5	23.9	22.4	25.0	21.2	21.8	14.9
	Missing	0.0	0.0	0.0	0.0	1.0	1.0	1.3
9h	Average duration of ESRD (years)	4.5	4.5	4.9	5.9	4.5	4.5	4.5
9i	Years since start of ESRD (% of 9a; sums to 100%)							
	< 1	22.4	18.2	18.8	11.3	18.9	19.4	17.5
	1-2	16.5	22.7	14.1	21.3	20.4	20.5	18.4
	2-3	16.5	14.8	16.5	11.3	13.5	13.8	14.
	3-6	17.6	19.3	23.5	22.5	24.7	24.2	26
	6+	27.1	25.0	27.1	33.8	22.5	22.1	23.0
9j	Nursing home patients (% of 9a) *3	8.2	13.6	17.6	15.0	13.8	12.6	12.
9k	Modality (% of 9a; sums to 100%)							
	In-center hemodialysis	98.8	100	98.8	97.5	86.3	84.6	89.9
	Home hemodialysis	0.0	0.0	1.2	1.3	3.3	2.6	1
	Continuous ambulatory peritoneal dialysis	0.0	0.0	0.0	0.0	2.0	2.7	2
	Continuous cycling peritoneal dialysis	0.0	0.0	0.0	0.0	7.6	9.4	5.
	Other modality *4	1.2	0.0	0.0	1.3	0.8	0.7	0.7

n/a = not applicable
[*1] See *Guide, Section XII.*[*2] Values are shown for the average facility.
[*3] Includes patients who were also treated by a nursing facility at any time during the year. The source of nursing facility history of patients is the Nursing Home Minimum Dataset.
[*4] Other modality includes other dialysis, uncertain modality, and patients not on dialysis but still temporarily assigned to the facility (discontinued dialysis, recovered renal function, and lost to follow up).

TABLE 10: Comorbidities Reported on Medicare Claims for Medicare Dialysis Patients Treated as of December 31 of Each Year *1, 2007-2009

		Th	is Facility	7	Regiona	l Averages *2	, 2009
	Measure Name	2007	2008	2009	State	Network	U.S.
10a	Medicare dialysis patients on 12/31 (n)	62	67	67	61.9	47.2	50.8
10b	Comorbidity (% yes of 10a)						
	AIDS/HIV positive	0.0	0.0	0.0	0.8	0.6	1.8
	Alcohol dependence	0.0	0.0	1.5	2.2	2.3	2.0
	Anemia	3.2	1.5	3.0	5.0	5.0	6.6
	Cancer	16.1	19.4	14.9	10.2	9.7	10.8
	Cardiac arrest	1.6	4.5	6.0	1.7	1.7	1.5
	Cardiac dysrhythmia	24.2	38.8	35.8	31.8	32.1	34.5
	Cerebrovascular disease	25.8	26.9	26.9	22.3	20.1	26.6
	Chronic obstructive pulmonary disease	16.1	17.9	20.9	24.8	24.2	29.1
	Congestive heart failure	37.1	28.4	32.8	43.4	42.4	50.8
	Diabetes	46.8	43.3	59.7	56.9	56.0	62.2
	Drug dependence	1.6	4.5	0.0	2.9	2.9	1.9
	Gastrointestinal tract bleeding	1.6	1.5	0.0	2.1	2.1	2.7
	Hepatitis B	0.0	0.0	0.0	1.2	0.9	1.1
	Hepatitis other	0.0	0.0	3.0	5.1	4.6	4.8
	Hyperparathyroidism	4.8	6.0	4.5	7.0	6.8	8.2
	Infection: dialysis access-related	9.7	16.4	17.9	16.3	16.5	18.9
	Infection: not related to dialysis access	48.4	50.7	52.2	45.5	42.9	49.8
	Ischemic heart disease	38.7	46.3	44.8	40.5	39.9	49.9
	Myocardial infarction	3.2	3.0	4.5	7.0	6.7	8.4
	Peripheral vascular disease *3	43.5	56.7	43.3	38.8	35.7	44.3
	Pneumonia	4.8	4.5	16.4	5.7	5.2	5.6
10c	Average number of comorbid conditions	3.3	3.7	3.9	3.7	3.6	4.2

n/a = not applicable
[*1] Based on patients with Medicare as primary insurer on 12/31 each year. See *Guide, Section XIII*.
[*2] Values are shown for the average facility.
[*3] Peripheral vascular disease includes both venous and arterial diseases.

TABLE 11: How Patients Were Assigned to This Facility and End of Year Patient Status *1 , 2007-2010

		This Facility				Regional Averages *2, 2010		
	Measure Name	2007	2008	2009	2010	State	Network	U.S.
11a	Number of patients placed in facility *1 (n)	120	126	118	117	104.0	86.5	90.9
11b	Initial patient placement for the year in this facility							
	(% of 11a; sums to 100%)							
	Continuing at facility on 01/01	70.0	66.7	74.6	72.6	67.4	67.0	69.0
	Incident (new to ESRD)	25.0	20.6	18.6	12.8	20.7	21.1	19.3
	Transferred into facility	5.0	12.7	6.8	14.5	12.0	11.8	11.7
11c	Patient status at end of year (% of 11a; sums to 100%)							
	Alive in this facility on 12/31	70.8	69.8	72.0	68.4	71.7	72.0	71.9
	Alive in another facility on 12/31	11.7	5.6	7.6	6.8	8.2	8.1	8.4
	Received a transplant	2.5	4.0	5.1	6.8	3.6	3.4	2.7
	Died; death attributed to this facility	10.0	17.5	11.9	12.8	13.6	13.5	13.5
	Died; death attributed to another facility	2.5	0.8	1.7	1.7	1.1	1.1	1.4
	Other*3	2.5	2.4	1.7	3.4	1.9	2.0	2.2

^[*1] Patient assignment for Tables 1,2,3,9, and 10 only. See *Guide, Section XIV*.
[*2] Values are shown for the average facility.
[*3] Includes patients who recovered renal function, discontinued dialysis, or were lost to follow-up. Also includes dialysis unrelated deaths. Dialysis unrelated deaths are not attributed to any facility for the purposes of the mortality calculations in this report.

TABLE 12: Patient and Staff Counts from the Annual Facility Survey (Form CMS-2744)*1, 2007-2010

		This Facility			Regional Averages *2, 2010			
	Measure Name	2007	2008	2009	2010	State	Network	U.S.
Pat	tients Treated During the Year							
12a	Patients treated during year (n)	133	146	140	135	119.0	98.6	103.3
12b	Incident patients (% of 12a)	21.8	19.2	17.1	15.6	19.1	20.1	19.0
12c	Transferred into facility (% of 12a)	9.8	16.4	13.6	14.8	15.6	15.0	13.0
12d	Transferred out of facility (% of 12a)	15.0	9.6	18.6	16.3	14.9	14.6	14.1
Pat	tients Treated on 12/31							
12e	Patients treated on 12/31 (n)	94	97	91	83	81.1	66.9	70.8
12f	Patient modality on 12/31 (n; sums to 12e)							
	In-center HD	94	97	91	83	70.9	57.3	64.2
	In-center CAPD	0	0	0	0	0.0	0.1	0.0
	In-center CCPD	0	0	0	0	0.0	0.0	0.0
	In-center Other	0	0	0	0	0.0	0.0	0.0
	Home HD	0	0	0	0	2.5	1.6	1.0
	Home CAPD	0	0	0	0	1.6	1.9	1.9
	Home CCPD	0	0	0	0	6.0	6.0	3.7
	Home Other	0	0	0	0	0.0	0.0	0.0
12g	Medicare eligibility status on 12/31 (% of 12e; sums to 100% *3)							
	Medicare	75.5	75.3	81.3	81.9	87.3	89.2	86.3
	Medicare application pending	11.7	11.3	9.9	7.2	6.7	5.7	9.3
	Non-Medicare	12.8	13.4	8.8	10.8	5.9	5.1	4.4
Fac	cility Staffing on 12/31 *4							
12h	Total full and part time staff positions (n)	24	25	30	25	19.3	15.7	14.0
12i	Staff positions by type (n; sums to 12h)							
	Full time nurse *5	5	5	7	5	5.0	4.5	4.7
	Full time patient care technician	8	9	5	8	7.1	5.8	5.2
	Full time renal dietician	0	0	0	0	0.4	0.4	0.5
	Full time social worker	0	0	0	0	0.5	0.4	0.5
	Part time nurse *5	4	5	4	4	2.5	1.6	1.0
	Part time patient care technician	5	4	11	5	2.2	1.5	0.8
	Part time renal dietician	1	1	2	2	0.8	0.8	0.6
	Part time social worker	1	1	1	1	0.7	0.7	0.6

^[*1] See Guide, Section XV.
[*2] Values are shown for the average facility.
[*3] Values may not sum to exactly 100% because of unknown Medicare status.
[*4] Data as of March 31, 2011. A full time position is defined as a position with at least 32 hours of employment a week and a part time position is defined as a position with less than 32 hours of employment a week (includes positions that were opened but not filled on this date).
[*5] Nursing staff includes registered nurse, licensed practical nurse, vocational nurse, or advanced practice nurse degree.

TABLE 13: Survey and Certification Activity*1, October 2008-June 2011

		This Facility		Regional Averages *2, October 2008-June 2011		
	Measure Name	Survey	State	Network	U.S.	
13a	Date of last survey	06/24/2010	n/a	n/a	n/a	
13b	Type of last survey	RECERTIFICATION	n/a	n/a	n/a	
13c	Compliance condition after last survey	Acceptable plan of correction	n/a	n/a	n/a	
13d	Number of deficiencies cited at last survey *3					
	Condition for coverage (CfC) deficiencies	0	0.2	0.3	0.4	
	Standard deficiencies	7	9.4	6.7	7.3	
13e	CfC deficiencies cited at last survey *3					
	V100 Compliance with Fed., State, and Local	No, not cited	0.0	0.0	0.1	
	V110 Infection Control	No, not cited	6.7	4.3	5.4	
	V175 Water and Dialysate Quality	No, not cited	0.0	4.3	4.3	
	V300 Reuse of Hemodialysis and Bloodlines	No, not cited	0.0	0.7	0.4	
	V400 Physical Environment	No, not cited	6.7	4.3	2.5	
	V450 Patient Rights	No, not cited	0.0	0.0	0.4	
	V500 Patient Assessment.	No, not cited	0.0	0.0	4.0	
	V540 Patient Plan of Care	No, not cited	0.0	2.1	4.7	
	V580 Care at Home	No, not cited	0.0	0.0	0.8	
	V625 Quality Assessment & Performance improvement	No, not cited	0.0	2.9	4.2	
	V660 Special Purpose Renal Dialysis Facilities	No, not cited	0.0	0.0	0.0	
	V675 Laboratory Services	No, not cited	0.0	0.7	0.1	
	V680 Personnel Qualifications	No, not cited	0.0	0.7	0.9	
	V710 Responsibilities of the Medical Director	No, not cited	0.0	2.1	4.7	
	V725 Medical Records	No, not cited	0.0	0.7	0.5	
	V759 Governance	No, not cited	1.7	3.6	4.6	

n/a = not applicable
[*1] See *Guide, Section XVI.*[*2] Average values are shown for the latest survey at each facility during the period October 2008 through June 2011. Some surveys from April through June of 2011 may not be included.
[*3] Values are shown for the latest survey at each facility during the period October 2008 through June 2011.

TABLE 14: Facility Information *1 , 2011

Field	This Facility				
Ownership:	Non-profit				
Organization:	REGIONAL-NORTHWEST KIDNEY CENTERS				
Initial Medicare certification date:	01/01/1981				
Number of stations:	18				
Services provided:	Hemodialysis and Peritoneal Dialysis				
Provider numbers included in this report:	502505				
National Provider Identifier (NPI) *2:	1215022876				

[*1] Information based on SIMS data as of March 31, 2011. See *Guide, Section XVII*. [*2] Information based on CROWNWEB data as of April 2011. If missing, data was not available.